keyword
MENU ▼
Read by QxMD icon Read
search

Mesothelin

keyword
https://www.readbyqxmd.com/read/29025836/assessment-of-potential-predictors-of-calretinin-and-mesothelin-to-improve-the-diagnostic-performance-to-detect-malignant-mesothelioma-results-from-a-population-based-cohort-study
#1
Swaantje Casjens, Daniel G Weber, Georg Johnen, Irina Raiko, Dirk Taeger, Carmen Meinig, Susanne Moebus, Karl-Heinz Jöckel, Thomas Brüning, Beate Pesch
OBJECTIVES: Mesothelin and calretinin are blood-based markers for malignant mesothelioma. The objective of this study was to analyse the markers in plasma samples from cancer-free men and to identify factors influencing their concentrations to minimise false-positive test results when using these markers for the early detection of malignant mesothelioma. SETTING: The present analyses used data and archived blood samples of the population-based Heinz Nixdorf Recall Study among elderly people collected from 2011 to 2014...
October 11, 2017: BMJ Open
https://www.readbyqxmd.com/read/28968445/pleural-effusion-biomarkers-and-computed-tomography-findings-in-diagnosing-malignant-pleural-mesothelioma-a-retrospective-study-in-a-single-center
#2
Takehiro Otoshi, Yuki Kataoka, Shunkichi Ikegaki, Emiko Saito, Hirotaka Matsumoto, Sawako Kaku, Masatoshi Shimada, Masataka Hirabayashi
In this study, we aimed to examine the clinical value of the pleural effusion (PE) biomarkers, soluble mesothelin-related peptide (SMRP), cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA), and the utility of combining chest computed tomography (CT) findings with these biomarkers, in diagnosing malignant pleural mesothelioma (MPM). We conducted a retrospective cohort study in a single center. Consecutive patients with undiagnosed pleural effusions who underwent PE analysis between September 2014 and August 2016 were reviewed...
2017: PloS One
https://www.readbyqxmd.com/read/28965877/mesothelin-specific-immune-responses-and-targeted-immunotherapy-for-mesothelin-expressing-tumors
#3
Takahiro Einama, Futoshi Kawamata, Hirofumi Kamachi, Hiroshi Nishihara, Shigenori Homma, Fumihiko Matsuzawa, Tatsuzo Mizukami, Yuji Konishi, Toshiya Kamiyama, Junji Yamamoto, Akinobu Taketomi, Satoru Todo
No abstract text is available yet for this article.
September 25, 2017: EBioMedicine
https://www.readbyqxmd.com/read/28964420/soluble-mesothelin-related-peptides-to-monitor-recurrence-after-resection-of-pleural-mesothelioma
#4
Bryan M Burt, Hyun-Sung Lee, Veronica Lenge De Rosen, Masatsugu Hamaji, Shawn S Groth, Thomas M Wheeler, David J Sugarbaker
BACKGROUND: Most patients undergoing surgical resection of malignant pleural mesothelioma (MPM) will experience recurrence, and radiographic diagnosis of recurrence can be difficult in the postoperative chest. Our objective was to determine the utility of the serum biomarker soluble mesothelin-related peptide (SMRP; or mesothelin) in monitoring of the postoperative MPM patient. METHODS: We retrospectively evaluated a prospectively maintained single institution clinical database...
September 27, 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28901470/tlr5-7-mediated-pi3k-activation-triggers-epithelial-mesenchymal-transition-of-ovarian-cancer-cells-through-wave3-dependent-mesothelin-or-oct4-sox2-expression
#5
Ga Bin Park, Daejin Kim
Toll-like receptor (TLR)-mediated signaling induces cell migration or invasion in several tumors and various stages of cancer. Interactions of mesothelin, a 40-kDa cell surface glycoprotein, with cancer antigen 125 (CA125) is associated with drug resistance, metastasis, and poor clinical outcome of ovarian cancer patients. In this study, we examined the role of TLR5 and TLR7 in the metastasis of ovarian cancer through the induction of mesothelin/CA125 expression and investigated its underlying mechanism. TLR5 agonist (flagellin) and TLR7 agonist (imiquimod) upregulated mesenchymal phenotypes and produced epithelial-mesenchymal transition (EMT)-related cytokines in the SKOV3 cells; however, TLR7 expressing CaOV3 cells had no response to the specific ligand, imiquimod, for enhancing its EMT processes...
September 6, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28898276/liver-myofibroblasts-of-murine-origins-express-mesothelin-identification-of-novel-rat-mesothelin-splice-variants
#6
Michel Fausther, Elise G Lavoie, Jonathan A Dranoff
Liver myofibroblasts are specialized effector cells that drive hepatic fibrosis, a hallmark process of chronic liver diseases, leading to progressive scar formation and organ failure. Liver myofibroblasts are increasingly recognized as heterogeneous with regards to their origin, phenotype, and functions. For instance, liver myofibroblasts express cell markers that are universally represented such as, ItgαV and Pdgfrβ, or restricted to a given subpopulation such as, Lrat exclusively expressed in hepatic stellate cells, and Gpm6a in mesothelial cells...
2017: PloS One
https://www.readbyqxmd.com/read/28888924/mesothelin-specific-immune-responses-predict-survival-of-patients-with-brain-metastasis
#7
Liu Zhenjiang, Martin Rao, Xiaohua Luo, Elisabeth Sandberg, Jiri Bartek, Esther Schoutrop, Anna von Landenberg, Qingda Meng, Davide Valentini, Thomas Poiret, Georges Sinclair, Inti-Harvey Peredo, Ernest Dodoo, Markus Maeurer
BACKGROUND: Patients with advanced malignancies, e.g. lung cancer, ovarian cancer or melanoma, frequently present with brain metastases. Clinical presentation and disease progression of cancer is in part shaped by the interaction of the immune system with malignant cells. Antigen-targeted immune responses have been implicated in the prolonged survival of patients with cancer. This includes the tumor-associated antigen (TAA) mature mesothelin, a 40kDa cell surface-bound antigen that is overexpressed in several malignancies including lung ovarian and pancreatic cancer...
September 2017: EBioMedicine
https://www.readbyqxmd.com/read/28841215/toll-like-receptor-2-costimulation-potentiates-the-antitumor-efficacy-of-car-t-cells
#8
Y Lai, J Weng, X Wei, L Qin, P Lai, R Zhao, Z Jiang, B Li, S Lin, S Wang, Q Wu, Z Tang, P Liu, D Pei, Y Yao, X Du, P Li
Chimeric antigen receptor (CAR) T-cell immunotherapies have shown unprecedented success in treating leukemia but limited clinical efficacy in solid tumors. Here, we generated 1928zT2 and m28zT2, targeting CD19 and mesothelin, respectively, by introducing the Toll/interleukin-1 receptor domain of Toll-like receptor 2 (TLR2) to 1928z and m28z. T cells expressing 1928zT2 or m28zT2 showed improved expansion, persistency and effector function against CD19(+) leukemia or mesothelin(+) solid tumors respectively in vitro and in vivo...
August 3, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28771103/overcoming-barriers-of-car-t-cell-therapy-in-patients-with-mesothelin-expressing-cancers
#9
Mark H O'Hara, Caitlin Stashwick, Gabriela Plesa, Janos L Tanyi
One obstacle to the application of immunotherapy to solid malignancies is to overcome the existing tolerance to self-antigens. Vaccine strategies aimed at harnessing endogenous antitumor T cells are limited by the T-cell receptor repertoire, which can be detected within the thymus as central tolerance or rendered nonfunctional by post-thymic mechanisms of peripheral tolerance. Adoptive immunotherapy can overcome these obstacles, since therapeutically effective T cells can be engineered to recognize tumors. Continued advancements in novel treatments, including immunotherapy, in solid malignancies are imperative...
August 2017: Immunotherapy
https://www.readbyqxmd.com/read/28740119/novel-insights-into-mesothelioma-biology-and-implications-for-therapy
#10
REVIEW
Timothy A Yap, Joachim G Aerts, Sanjay Popat, Dean A Fennell
Malignant mesothelioma is a universally lethal cancer that is increasing in incidence worldwide. There is a dearth of effective therapies, with only one treatment (pemetrexed and cisplatin combination chemotherapy) approved in the past 13 years. However, the past 5 years have witnessed an exponential growth in our understanding of mesothelioma pathobiology, which is set to revolutionize therapeutic strategies. From a genomic standpoint, mesothelioma is characterized by a preponderance of tumour suppressor alterations, for which novel therapies are currently in development...
July 25, 2017: Nature Reviews. Cancer
https://www.readbyqxmd.com/read/28713675/novel-systemic-therapy-against-malignant-pleural-mesothelioma
#11
REVIEW
Michael R Mancuso, Joel W Neal
Malignant pleural mesothelioma is an aggressive tumor of the pleura with an overall poor prognosis. Even with surgical resection, for which only a subset of patients are eligible, long term disease free survival is rare. Standard first-line systemic treatment consists of a platinum analog, an anti-metabolite, and sometimes anti-angiogenic therapy, but there is currently no well-established standard therapy for refractory or relapsed disease. This review focuses on efforts to develop improved systemic therapy for the treatment of malignant pleural mesothelioma (MPM) including cytotoxic systemic therapy, a variety of tyrosine kinase inhibitors and their downstream effector pathways, pharmacologic targeting of the epigenome, novel approaches to target proteins expressed on mesothelioma cells (such as mesothelin), arginine depletion therapy, and the emerging role of immunotherapy...
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28713671/diagnostic-and-prognostic-biomarkers-for-malignant-mesothelioma-an-update
#12
REVIEW
Zhongjian Chen, Giovanni Gaudino, Harvey I Pass, Michele Carbone, Haining Yang
Malignant mesothelioma (MM) is an aggressive and lethal cancer, mostly related to inhalation of asbestos and erionite fibers. MM is associated with poor prognosis, because of its resistance to current therapies, even if higher survival occurs in patients diagnosed and treated when at stage I of the disease. However, these do not exceed 5% of the total number of cases, due to the inadequacy of the existing biomarkers for early and accurate diagnosis. Therefore, new effective biomarkers are needed for MM detection at earlier stages and to develop tailored therapies...
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28706912/diagnosis-and-prognosis-review-of-biomarkers-for-mesothelioma
#13
REVIEW
Huan H Sun, Allen Vaynblat, Harvey I Pass
Malignant pleural mesothelioma (MPM) is an aggressive disease arising in pleural cell lining and is associated with asbestos exposure. Today, there is a rising incidence of MPM reaching 3,000 annual cases nationally, primarily from the large population occupationally exposed to asbestos between 1940 and 1980. With a prolonged latency period, presenting clinically 10 to 40 years after exposure, MPM is often diagnosed in late stages and presents median survival time of less than 12 months. There is a serious need for improvement in prognostic and diagnostic tools for MPM...
June 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/28674083/combining-local-immunotoxins-targeting-mesothelin-with-ctla-4-blockade-synergistically-eradicates-murine-cancer-by-promoting-anticancer-immunity
#14
Yasmin Leshem, James O'Brien, Xiufen Liu, Tapan K Bera, Masaki Terabe, Jay A Berzofsky, Birgit Bossenmaier, Gerhard Niederfellner, Chin-Hsien Tai, Yoram Reiter, Ira Pastan
Immune checkpoint blockade using antibodies to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) benefits a limited number of cancer patients. SS1P and LMB-100 are immunotoxins that target mesothelin. We observed delayed responses to SS1P in patients with mesothelioma suggesting that antitumor immunity was induced. Our goal was to stimulate antitumor immunity by combining SS1P or LMB-100 with anti-CTLA-4. We constructed a BALB/c breast cancer cell line expressing human mesothelin (66C14-M), which was implanted in one or two locations...
August 2017: Cancer Immunology Research
https://www.readbyqxmd.com/read/28652837/a-pilot-study-of-zoledronic-acid-in-the-treatment-of-patients-with-advanced-malignant-pleural-mesothelioma
#15
Muhammad Omer Jamil, Mary S Jerome, Deborah Miley, Katri S Selander, Francisco Robert
PURPOSE: Malignant pleural mesothelioma (MPM) is a rare malignancy with a dismal median survival of <12 months with current therapy. Single and combination chemotherapy regimens have shown only modest clinical benefit. In preclinical studies, nitrogen-containing bisphosphonates (zoledronic acid) inhibit growth of mesothelioma cells by different mechanisms: inhibition of mevalonate pathway, inhibition of angiogenesis, activation of apoptosis through caspase activation, and alteration in activity of matrix metalloproteinases, thereby affecting invasiveness of cancer cells...
2017: Lung Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28640856/correction-msln-gene-silencing-has-an-anti-malignant-effect-on-cell-lines-overexpressing-mesothelin-deriving-from-malignant-pleural-mesothelioma
#16
Ombretta Melaiu, Justin Stebbing, Ylenia Lombardo, Elisa Bracci, Norihisa Uehara, Alessandra Bonotti, Alfonso Cristaudo, Rudy Foddis, Luciano Mutti, Roberto Barale, Federica Gemignani, Georgios Giamas, Stefano Landi
[This corrects the article DOI: 10.1371/journal.pone.0085935.].
2017: PloS One
https://www.readbyqxmd.com/read/28638449/plasma-mesothelin-as-a-novel-diagnostic-and-prognostic-biomarker-in-colorectal-cancer
#17
Shuwei Li, Lisheng Xie, Lei He, Zhimin Fan, Junhua Xu, Kaili Xu, Lingjun Zhu, Gaoxiang Ma, Mulong Du, Haiyan Chu, Zhengdong Zhang, Min Ni, Meilin Wang
Objective Mesothelin is a cell surface protein and overexpressed in many cancers. However, the potential value of mesothelin as plasma biomarker in colorectal cancer has not been explored. The purpose of this study was to identify whether plasma mesothelin is a suitable diagnostic and prognostic biomarker for colorectal cancer. Methods We performed a two-stage case-control study to evaluate plasma mesothelin levels in colorectal cancer using enzyme-linked immunosorbent assay (ELISA). Preoperative and postoperative plasma were collected to examine the level changes influenced by surgery...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28558669/calretinin-as-a-blood-based-biomarker-for-mesothelioma
#18
Georg Johnen, Katarzyna Gawrych, Irina Raiko, Swaantje Casjens, Beate Pesch, Daniel G Weber, Dirk Taeger, Martin Lehnert, Jens Kollmeier, Torsten Bauer, Arthur W Musk, Bruce W S Robinson, Thomas Brüning, Jenette Creaney
BACKGROUND: Malignant mesothelioma (MM) is a deadly cancer mainly caused by previous exposure to asbestos. With a latency period up to 50 years the incidence of MM is still increasing, even in countries that banned asbestos. Secondary prevention has been established to provide persons at risk regular health examinations. An earlier detection with tumor markers might improve therapeutic options. Previously, we have developed a new blood-based assay for the protein marker calretinin. Aim of this study was the verification of the assay in an independent study population and comparison with the established marker mesothelin...
May 30, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28540060/microparticle-formation-in-peritoneal-dialysis-a-proof-of-concept-study
#19
Shareef Akbari, Rima Abou-Arkoub, Suzy Sun, Swapnil Hiremath, Arkadiy Reunov, Brendan B McCormick, Marcel Ruzicka, Dylan Burger
BACKGROUND: Injury to the mesothelial layer of the peritoneal membrane during peritoneal dialysis (PD) is implicated in loss of ultrafiltration capacity, but there are no validated biomarkers for mesothelial cell injury. Microparticles (MPs) are 0.1 to 1.0 µm membrane vesicles shed from the cell surface following injury and are sensitive markers of tissue damage. Formation of MPs in the peritoneal cavity during PD has not been reported to date. METHODS: We designed a single-center, proof of concept study to assess whether peritoneal solution exposure induces formation of mesothelial MPs suggestive of PD membrane injury...
2017: Canadian Journal of Kidney Health and Disease
https://www.readbyqxmd.com/read/28507279/prognostic-significance-of-soluble-mesothelin-in-malignant-pleural-mesothelioma-a-meta-analysis
#20
Long Tian, Rujun Zeng, Xin Wang, Cheng Shen, Yutian Lai, Mingming Wang, Guowei Che
BACKGROUND: Soluble mesothelin is beneficial to detect the progression and the treatment response of malignant pleural mesothelioma. However, the prognostic value of soluble mesothelin in malignant pleural mesothelioma remains unclear. METHODS: Hazard ratio with 95% CI was used to evaluate the prognostic value of soluble mesothelin and the effect of clinicopathological characteristics on the survival of malignant pleural mesothelioma. RESULTS: Eight eligible studies involving 579 patients were selected for this meta-analysis...
July 11, 2017: Oncotarget
keyword
keyword
41012
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"